About Gain Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.gaintherapeutics.com/
Frequently Asked Questions
What is the 52-week range for GANX?
The 52-week high is $4.34 and the 52-week low is $1.53.
What is the P/E ratio for GANX?
The P/E ratio data is currently unavailable.
What is the dividend yield for GANX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -161.58%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -6393.75%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 6.67.
Analyst Recommendation Trends
Wall Street analyst consensus for GANX over the last few months:
Latest GANX News
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration of rexaceract by August 31, 2026 Participants with both high and low baseline levels of GluSph experienced stabilization of MDS-UPDRS motor scores by 12 months Results support disease-modifying potential of rexaceract along with a favorable tolerability profile; no significant safety signals observed
Gain Therapeutics Announces Poster Presentation At International Congress Of Parkinson’s Disease And Movement Disorders, October 4-8; MDS-UPDRS Motor Scores Demonstrated Stability To Baseline Recorded At Study Entry With No Disease Progression Among The 12 Evaluable Participants; Results Support Disease-Modifying Potential Of Rexaceract
Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule
Gain Therapeutics Plans To Initiate Phase 2 Rexaceract Trial In Q1 Next Year
https://www.sec.gov/ix?doc=/Archives/edgar/data/1819411/000110465926112624/tm2626750d1_8k.htm
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at the International Congress of Parkinson’s Disease and Movement Disorders, being held October 4-8, 2026, in Seoul, Korea. Details of the poster and presentation are as follows: Poster Title: Long-Term Op
Gain Therapeutics Reveals Poster Presentation At International Congress Of Parkinson’s Disease and Movement Disorders
Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule
Gain Therapeutics Appoints CEO Gene Mack As Interim CFO, Effective Oct. 1, Succeeding Principal Financial Officer Gianluca Fuggetta
https://www.sec.gov/ix?doc=/Archives/edgar/data/1819411/000110465926111391/tm2626106d1_8k.htm
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
BETHESDA, Md., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in an industry panel and one-on-one meetings at the ROTH Fifth Annual Healthcare Opportunities Conference, held September 29th at the Metropolitan Club in New York, NY. Present
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-15 | Islam Khalid | +25,000 | - | - |
| 2026-07-15 | Nicaise Claude | +25,000 | - | - |
| 2026-07-15 | Melincoff Gwen A | +25,000 | - | - |
| 2026-07-15 | Riley Jeffrey Scott | +25,000 | - | - |
| 2026-07-15 | HASLER HANS PETER | +25,000 | - | - |
| 2026-07-15 | GOLDSTEIN DOV A MD | +25,000 | - | - |
| 2026-03-24 | Fuggetta Gianluca | +50,000 | - | - |
| 2026-03-24 | Mack Gene | +200,000 | - | - |